- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07546448
Elektrolity surowicy a nefropatia wywołana środkiem kontrastowym u pacjentów z ostrym udarem niedokrwiennym mózgu poddawanych leczeniu endowaskularnemu
Wpływ stężeń elektrolitów w surowicy na ryzyko nefropatii indukowanej kontrastem u pacjentów z ostrym niedokrwiennym udarem mózgu poddawanych leczeniu wewnątrznaczyniowemu
This study aims to evaluate the relationship between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients with acute ischemic stroke undergoing endovascular therapy (EVT).
Contrast-induced nephropathy remains a significant complication associated with endovascular procedures and is linked to increased morbidity and mortality. While several risk factors have been identified, the role of serum electrolyte imbalances in the development of CI-AKI has not been fully elucidated.
In this retrospective cohort study, patients treated with EVT between 2018 and 2026 will be analyzed. Patients will be classified based on the presence or absence of CI-AKI according to changes in serum creatinine levels. Demographic data, comorbidities, laboratory parameters-including serum electrolytes-and procedural variables will be compared between groups.
The primary objective is to determine whether serum electrolyte levels are associated with the risk of CI-AKI. Secondary objectives include evaluating 90-day mortality and dialysis dependency in patients who develop CI-AKI.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
This retrospective cohort study is designed to evaluate the association between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients undergoing endovascular therapy (EVT) for acute ischemic stroke.
Endovascular treatment has become a standard of care for acute ischemic stroke; however, the use of iodinated contrast media carries a risk of nephrotoxicity. Contrast-induced acute kidney injury remains a clinically significant complication and is associated with prolonged hospitalization, increased healthcare costs, and higher mortality rates. Although several well-established risk factors for CI-AKI have been identified, including baseline renal dysfunction, diabetes mellitus, and contrast volume, the role of serum electrolyte imbalances has not been clearly defined.
Electrolyte disturbances may influence renal perfusion, tubular function, and systemic hemodynamics, potentially contributing to the pathophysiology of CI-AKI. Therefore, identifying electrolyte-related risk factors may help improve risk stratification and guide preventive strategies in high-risk populations.
In this study, patients who underwent EVT between 2018 and 2026 will be included. Prospectively collected clinical data will be analyzed retrospectively. Patients will be divided into two groups based on the development of CI-AKI, defined according to changes in serum creatinine levels following contrast exposure.
Comparative analyses will be performed between patients with and without CI-AKI to identify potential predictors. Multivariate regression analysis may be used to determine independent risk factors associated with CI-AKI development.
The findings of this study are expected to provide clinically relevant insights into the role of electrolyte balance in the development of CI-AKI and may contribute to improved peri-procedural risk assessment and patient management strategies in acute ischemic stroke populations undergoing endovascular therapy.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Outside of the US
-
Diyarbakır, Outside of the US, Turcja (Türkiye), 21070
- Fatma Acil
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
This study includes adult patients (≥18 years) with acute ischemic stroke who underwent endovascular therapy at a tertiary referral center between 2018 and 2026. Patients with sufficient clinical and laboratory data, including pre- and post-procedural serum creatinine measurements, will be eligible for inclusion.
The cohort reflects a real-world population of patients undergoing EVT, encompassing a wide range of demographic and clinical characteristics, including common vascular comorbidities. Patients will be stratified according to the development of contrast-induced acute kidney injury (CI-AKI) for comparative analyses.
Opis
Inclusion Criteria:
- Adults aged 18 years or older
- Patients diagnosed with acute ischemic stroke
- Patients who underwent endovascular therapy for acute ischemic stroke between 2018 and 2026
- Patients with a baseline NIHSS score of 6 or higher
- Patients who received iodinated contrast medium during the endovascular procedure
- Patients managed under general anesthesia
- Patients with available pre-procedural and post-procedural serum creatinine measurements sufficient to assess contrast-induced acute kidney injury
Exclusion Criteria:
- Age younger than 18 years
- Pre-existing acute kidney injury or chronic kidney disease meeting KDIGO stage 1-3 before endovascular therapy
- APACHE score greater than 25 at the time of the procedure
- Known allergy or hypersensitivity to iodinated contrast media
- Exposure to iodinated contrast media within the previous 2 weeks
- Use of nephrotoxic medications within the previous 2 weeks
- History of myocardial infarction or previous stroke
- Use of vasopressor/inotropic agents such as dopamine at the time of the procedure
- Systemic steroid use at the time of the procedure
- Incomplete medical records or missing laboratory data required for evaluation of CI-AKI
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: RETROSPECTIVE
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
CI-AKI Group
Patients who developed contrast-induced acute kidney injury (CI-AKI) following endovascular therapy for acute ischemic stroke, defined by an increase in serum creatinine levels according to established diagnostic criteria after contrast exposure. These patients were identified based on post-procedural renal function changes and included in the analysis to evaluate clinical, laboratory, and procedural factors associated with CI-AKI development. |
No experimental or therapeutic intervention was assigned. This observational retrospective cohort study evaluated patients undergoing endovascular therapy for acute ischemic stroke, who were subsequently categorized based on the presence or absence of contrast-induced acute kidney injury (CI-AKI). The study analyzed demographic, clinical, laboratory (including serum electrolyte levels) and procedural variables to identify potential risk factors associated with CI-AKI development. |
|
Non-CI-AKI Group
Patients who underwent endovascular therapy for acute ischemic stroke but did not develop contrast-induced acute kidney injury based on post-procedural serum creatinine measurements. |
No experimental or therapeutic intervention was assigned. This observational retrospective cohort study evaluated patients undergoing endovascular therapy for acute ischemic stroke, who were subsequently categorized based on the presence or absence of contrast-induced acute kidney injury (CI-AKI). The study analyzed demographic, clinical, laboratory (including serum electrolyte levels) and procedural variables to identify potential risk factors associated with CI-AKI development. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Incidence of contrast-induced acute kidney injury (CI-AKI)
Ramy czasowe: Within 48-72 hours after contrast exposure
|
CI-AKI will be identified based on post-procedural serum creatinine changes after contrast exposure according to established diagnostic criteria. |
Within 48-72 hours after contrast exposure
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
90-day mortality
Ramy czasowe: Within 90 days after endovascular therapy
|
All-cause mortality occurring within 90 days after endovascular therapy in patients with and without contrast-induced acute kidney injury (CI-AKI). |
Within 90 days after endovascular therapy
|
|
Dialysis dependency in patients with CI-AKI
Ramy czasowe: Within 90 days after endovascular therapy
|
Requirement for renal replacement therapy (hemodialysis) within 90 days after endovascular therapy in patients who developed contrast-induced acute kidney injury (CI-AKI) |
Within 90 days after endovascular therapy
|
|
Change in serum creatinine
Ramy czasowe: Baseline to 48-72 hours after endovascular therapy
|
Change in serum creatinine levels from baseline to post-procedural measurements following contrast exposure. |
Baseline to 48-72 hours after endovascular therapy
|
|
Association between serum electrolyte levels and CI-AKI
Ramy czasowe: Baseline (pre-procedural measurements)
|
Evaluation of the relationship between baseline serum electrolyte levels (sodium, potassium, chloride, calcium, magnesium, phosphate) and the development of contrast-induced acute kidney injury. |
Baseline (pre-procedural measurements)
|
|
Length of hospital stay
Ramy czasowe: Within 90 days after endovascular therapy
|
Total duration of hospitalization in days, compared between patients with and without CI-AKI. |
Within 90 days after endovascular therapy
|
|
Inflammatory markers and CI-AKI relationship
Ramy czasowe: Baseline (pre-procedural measurements)
|
Association between inflammatory markers (e.g., C-reactive protein, procalcitonin) and the development of CI-AKI. |
Baseline (pre-procedural measurements)
|
|
Change in estimated glomerular filtration rate (eGFR)
Ramy czasowe: Baseline to 48-72 hours after endovascular therapy
|
Change in estimated glomerular filtration rate (eGFR) from baseline to post-procedural measurements following contrast exposure |
Baseline to 48-72 hours after endovascular therapy
|
Współpracownicy i badacze
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Zaburzenia naczyniowo-mózgowe
- Choroby mózgu
- Choroby ośrodkowego układu nerwowego
- Choroby Układu Nerwowego
- Choroby naczyniowe
- Choroby układu krążenia
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby nerek
- Choroby Urologiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Niewydolność nerek
- Uderzenie
- Udar niedokrwienny
- Ostre uszkodzenie nerek
Inne numery identyfikacyjne badania
- 27.012.2026-37
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .